Cue Biopharma is expected to report a third-quarter revenue consensus of $1.55 million and an EPS estimate of -$4.04, with the stock currently trading at approximately $14.10 against an average analyst price target of $88.00.

Investors are primarily focused on the company’s cash runway and liquidity, as high R&D burn rates following a strategic transformation continue to pressure the balance sheet.

The company recently completed a 1-for-30 reverse split to maintain Nasdaq compliance, significantly shifting per-share metrics and targets. While clinical progress in the CUE-221 program for chronic hives has shown promise, the market remains cautious about the timing of future collaboration milestones and potential dilutive financing needs.